Osteogenic Growth Peptide (10-14) (Synonyms: OGP(10-14); Historphin) |
| Katalog-Nr.GA23328 |
Osteogenes Wachstumspeptid (10-14) (OGP(10-14)), das C-terminal verkÜrzte Pentapeptid des osteogenen Wachstumspeptids (OGP), behÄlt die volle OGP-Ähnliche AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 105250-85-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Osteogenic Growth Peptide (10-14) is a truncated pentapeptide fragment of the active osteogenic growth peptide (OGP) and is a Src kinase (Src) inhibitor [1-2]. Osteogenic Growth Peptide (10-14) binds to the OGP receptor and activates the Gi protein-MAP kinase signaling pathway [3]. Osteogenic Growth Peptide (10-14) is a potent mitogen and bone formation and hematopoietic stimulator, which can be used to treat osteoporosis and periodontitis [4].
In vitro, Osteogenic Growth Peptide (10-14) (0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days) treated human periodontal ligament stem cells (hPDLSCs), and at low concentrations (0.01, 0.1, and 1nM), it significantly enhanced cell proliferation and osteogenic differentiation potential, while at concentrations of 10 and 100nM, there was no related response [5]. Osteogenic Growth Peptide (10-14) (0.1nM; 7-21 days) treatment significantly promoted osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs), inhibited adipocyte formation, increased alkaline phosphatase (ALP) activity and mineralization nodules formation, and stimulated osteoblast-specific mRNA expression of nuclear factor 1 (cbfa1), and inhibited adipocyte-specific mRNA expression of peroxisome proliferator-activated receptor gamma-2 (PPARγ2) [6].
In vivo, Osteogenic Growth Peptide (10-14) (1nmol/kg/day; 35 days; s.c.) could significantly alleviate bone loss in female mice that underwent ovarian removal (OVX) 30 days before the start of anabolic therapy, and increase the number of osteogenic cells in the mice [7].
References:
[1] Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.
[2] Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.
[3] Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.
[4] Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1)
[5] Purbantoro S D, Osathanon T, Nantavisai S, et al. Osteogenic growth peptide enhances osteogenic differentiation of human periodontal ligament stem cells[J]. Heliyon, 2022, 8(7).
[6] Chen ZX, Chang M, Peng YL, et al. Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Pept. 2007;142(1-2):16-23.
[7] Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design[J]. Peptide Science: Original Research on Biomolecules, 2002, 66(1): 33-48.
| Cell experiment [1]: | |
Cell lines | Human periodontal ligament stem cells (hPDLSCs) |
Preparation Method | Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), 1% Antibiotic-Antimycotic, and 1% Glutamax. The isolated cells were incubated at 37°C with 5%CO2. Growth medium was changed every 48h and subcultured at 80% confluence. For Osteogenic Growth Peptide (10-14) treatment, hPDLSCs were cultured with Osteogenic Growth Peptide (10-14) supplemented in culture medium at concentrations of 0.01, 0.1, 1, 10, and 100nM. After Osteogenic Growth Peptide (10-14) treatment for 1, 5, and 7 days in growth medium, live/dead assay was performed by using calcein-AM and propidium iodide (PI) to stain OGP-untreated and -treated hPDLSCs. Cells were seeded at the density of 5 × 103 cells per well in a 24-well culture plate. Carl Zeiss™ Apoptome.2 apparatus-equipped fluorescent microscope was used to evaluate the stained cells. |
Reaction Conditions | 0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days |
Applications | At low concentrations (0.01, 0.1, and 1nM), Osteogenic Growth Peptide (10-14) significantly enhanced cell proliferation, while at concentrations of 10 and 100nM, no corresponding effects were observed. |
References: | |
| Cas No. | 105250-85-9 | SDF | |
| Überlieferungen | OGP(10-14); Historphin | ||
| Formula | C24H29N5O7 | M.Wt | 499.52 |
| Löslichkeit | DMSO : 8.93 mg/mL (17.88 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0019 mL | 10.0096 mL | 20.0192 mL |
| 5 mM | 400.4 μL | 2.0019 mL | 4.0038 mL |
| 10 mM | 200.2 μL | 1.001 mL | 2.0019 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *